Your browser doesn't support javascript.
loading
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07.
Kim, Miso; Keam, Bhumsuk; Ock, Chan-Young; Kim, Se Hyun; Kim, Yu Jung; Lim, Sun Min; Kim, Jin-Soo; Kim, Tae Min; Hong, Sook-Hee; Ahn, Mi Sun; Shin, Seong Hoon; Kang, Eun Joo; Kim, Dong-Wan; Im, Sun-Wha; Kim, Jong-Il; Lee, Jong Seok; Kim, Joo-Hang; Heo, Dae Seog.
Afiliação
  • Kim M; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Keam B; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Ock CY; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim SH; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim YJ; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Lim SM; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  • Kim TM; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  • Hong SH; Department of Internal Medicine, CHA Bundang Medical Center, Seongnam, Republic of Korea.
  • Ahn MS; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
  • Shin SH; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kang EJ; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim DW; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Im SW; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea.
  • Kim JI; Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea.
  • Lee JS; Department of Internal Medicine, Korea University Medical Center, Korea University College of Medicine, Seoul, Republic of Korea.
  • Kim JH; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Heo DS; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Thorac Cancer ; 11(12): 3482-3489, 2020 12.
Article em En | MEDLINE | ID: mdl-33026712
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Imunoterapia / Neoplasias Pulmonares / Anticorpos Monoclonais Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Thorac Cancer Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Imunoterapia / Neoplasias Pulmonares / Anticorpos Monoclonais Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Thorac Cancer Ano de publicação: 2020 Tipo de documento: Article